International Journal of Psychiatry in Clinical Practice
July 10, 2025
Stefan Jerotić, Milica Nestorovic, Janko Nešić et al.
3 citations
These two cases highlight the utility of a focused, structured clinical phenomenological interview in measuring treatment effectiveness in subjective experience. Two male patients, aged 35 and 27, of Serbian ethnicity with treatment-resistant depression were treated with nasal esketamine, with clinical progress monitored using both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the...
Psychology in the Schools
July 9, 2025
Kenjiro Tsubono, Sachiko Mitoku
Schoolteachers are considered as one of the most stressful professions worldwide. This study aimed to investigate the effect of brief mindfulness meditation practice via video streaming on schoolteachers' mental health. Public school teachers were recruited through paper flyers and relevant social media. Participants were randomly assigned to either the meditation or the control group. Blind...
Scientific Reports
July 8, 2025
Beenish Asrar, Nouman Ali, Imran Ali et al.
Major depressive disorder (MDD) and Attention-deficit hyperactivity disorder (ADHD) are pervasive psychiatric disorders characterized by impaired memory, sustained attention/motivation, and depression. FDA-approved Ketamine is an antidepressant drug but it affects cognitive abilities. Methylphenidate is the drug used for the treatment of ADHD. Chronic treatment overcomes attention and mental...
Explore
July 8, 2025
Ying-Ju Chen, Chiu-Hsiang Lee, Chia-Jung Hsieh et al.
1 citation
Online mindfulness may be an effective non-pharmacological mental health intervention. To evaluate the effectiveness of an online mindfulness platform in ameliorating anxiety, depression, and stress in patients with chronic diseases. In this randomized controlled study, 97 patients were enrolled and randomly assigned to either the online intervention group (N = 47) or the control group (N =...
Biochemical and Biophysical Research Communications
July 8, 2025
Jiaxin Tian, Yanhong Xie, Sen Ye et al.
6 citations
The available therapeutic options for post-stroke depression patients are limited. Although SSRIs are the most commonly prescribed antidepressants, their slow onset of action and the higher risk of adverse effects or contraindications have led to an urgent need to develop fast-acting and highly specific antidepressants tailored to the needs of PSD patients. Therefore, ketamine has drawn...
July 7, 2025
Balázs Szigeti
preprint
Background: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to theoretical concerns of precipitating mania or psychosis. Although psilocybin has demonstrated antidepressant effects when combined with psychotherapy, adverse event reporting is inconsistent, and restrictive eligibility criteria...
Arts, Culture and Language
July 6, 2025
Yutong Song
Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeutic benefits of psilocybin has led to...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
July 5, 2025
Verina Guirguis, Sanvi Korsapathy, Francesca Pupillo et al.
6 citations
Nasal Esketamine is a rapid-acting intervention for depression, hypothesized to exert its effects through cortical disinhibition. However, the spatio-temporal dynamics of brain network activity and their relationship to the subjective drug experience following Esketamine administration remain elusive. This observational study aims to delineate brain network-level effects of Esketamine by...
Journal of Psychosomatic Research
July 5, 2025
Ema Štánerová, Veronika Zelenayová, Jakub Rajčáni
8 citations
Mindfulness interventions are indicated to be effective in reducing psychological symptoms faced by patients with cancer. However, there is a lack of revised evidence on their effectiveness during the active treatment phase. To address this research gap, we conducted a meta-analysis of controlled clinical trials with adult patients written in English, published in PubMed, Web of Science,...
JAMA Psychiatry
July 2, 2025
Adam Janik, Xin Qiu, Rosanne Lane et al.
40 citations
Esketamine nasal spray, administered in conjunction with an oral antidepressant, is approved for treatment-resistant depression (TRD). However, the efficacy of esketamine nasal spray administered as monotherapy for patients with TRD has not yet been evaluated. To assess the efficacy and safety of esketamine monotherapy compared to placebo in reducing depressive symptoms in patients with TRD....